Live feed07:05:00·31dPRReleasevia QuantisnowSonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancersByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care